FDA greenlights ViiV’s Tivicay PD for HIV-positive newborns in first month of life

The FDA has approved ViiV Healthcare’s Tivicay PD (dolutegravir) for treating HIV-1 in pediatric patients weighing at least 2 kg, including eligible newborns, the company and FDA announced. FDA first approved Tivicay in August 2013 for adults and adolescents aged 12 or older weighing at least 40 kg (about 88.2 pounds). The agency approved the… The post FDA greenlights ViiV’s Tivicay PD for…